Regulation of the sympathetic nervous system by the kidney

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 1, 2014, Pages 61-68

  Larsen, Robyn ^a   Thorp, Alicia ^a,b   Schlaich, Markus ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

angiotensin II; kidney; obesity; renal denervation; sympathetic nerve activity

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; GHRELIN; LEPTIN; NEUROPEPTIDE Y; NORADRENALIN; RENIN; TUMOR NECROSIS FACTOR ALPHA; VASOPRESSIN;

ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; ARTERIAL PRESSURE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CAROTID SINUS PRESSORECEPTOR REFLEX; CLINICAL EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; EFFERENT NERVE; FAT INTAKE; FLUID RETENTION; HORMONE ACTION; HUMAN; HYPERTENSION; HYPOTHALAMUS; JUXTAGLOMERULAR CELL; KIDNEY DENERVATION; KIDNEY FUNCTION; KIDNEY PARENCHYMA; MEAN ARTERIAL PRESSURE; MEDULLA OBLONGATA; META ANALYSIS (TOPIC); NERVE CELL STIMULATION; NONHUMAN; NORADRENALIN RELEASE; OBESITY; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; RENIN RELEASE; REVIEW; ROSTRAL VENTROLATERAL MEDULLA; SODIUM INTAKE; SOLITARY TRACT NUCLEUS; SPONTANEOUSLY HYPERTENSIVE RAT; SPRAGUE DAWLEY RAT; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; WHITE ADIPOSE TISSUE;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; KIDNEY; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84890552074     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000437610.65287.db     Document Type: Review

References (54)

1. Zubcevic J, Waki H, Raizada MK, et al. Autonomic-immune-vascular interaction: An emerging concept for neurogenic hypertension. Hypertension 2011; 57:1026-1033.
2. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77:75-197.
3. DiBona G, Kopp U. Neural control of the kidney: Past, present and future. Hypertension 2003; 41:621-624.
4. Hall JE, Brands MW. The renin-angiotnesin-aldosterone system: Renal mechanisms and circulatory homeostasis. In: The Kidney: Physiology, pathophysiology. Philadelphia: Lippincott Williams & Wilkins; 2000; pp. 1009-1046.
5. Kopp UC, Olson LA, DiBona GF. Renorenal reflex responses to mechanoand chemoreceptor stimulation in the dog and rat. Am J Physiol 1984; 246:F67-F77.
6. Esler M, Lambert G, Jennings G. Increased regional sympathetic nervous activity in human hypertension: Causes and consequences. J Hypertens Suppl 1990; 8:S53-S57.
7. Anderson EA, Sinkey CA, Lawton WJ, et al. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 1989; 14:177-183.
8. Grassi G, Colombo M, Seravalle G, et al. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 1998; 31:64-67.
9. Kopp U, Cicha M, Smith L. Impaired interaction between efferent and afferent nerve activity in SHR involves increased activation of alpha2-adrenoreceptors. Hypertension 2011; 57:640-647.
10. Kopp UC, Cicha MZ, Smith LA, et al. Dietary sodium modulates the interaction between efferent and afferent renal nerve activity by altering activation of alpha2-adrenoceptors on renal sensory nerves. Am J Physiol Regul Integr Comp Physiol 2011; 300:R298-R310.
11. Sanchez A, Pettinger WA. Dietary sodium regulation of blood pressure and renal alpha 1-and alpha 2-receptors in WKY and SH rats. Life Sci 1981; 29:2795-2802.
12. Johns EJ, Kopp UC. Neural control of renal function. The kidney: Physiology, pathophysiology. 4th ed. Boston, MA, USA: Academic Press; 2008; pp. 925-946.
13. Vari RC, Zinn S, Verburg KM, et al. Renal nerves and the pathogenesis of angiotensin-induced hypertension. Hypertension 1987; 9:345-349.
14. Barrett CJ, Ramchandra R, Guild SJ, et al. What sets the long-term level of renal sympathetic nerve activity: A role for angiotensin II and baroreflexes Circ Res 2003; 92:1330-1336.
15. Carroll R, Lohmeier T, Brown A. Chronic angiotensin II infusion decreases renal norepinephrine overflow in conscious dogs. Hypertension 1987; 6:675-681.
16. Lohmeier T. Angiotensin II infusion model of hypertension: Is there an important sympathetic component Hypertension 2012; 59:539-541.
17. Moretti JL, Burke SL, Davern PJ, et al. Renal sympathetic activation from longterm low-dose angiotensin II infusion in rabbits. J Hypertens 2012; 30:551-560. Using direct measurements of RSNA, this study provides important evidence on the causative role of Ang II in the activation of renal sympathetic activation at rest and in response to stress
18. Guild SJ, McBryde FD, Malpas SC, et al. High dietary salt and angiotensin II chronically increase renal sympathetic nerve activity: A direct telemetric study. Hypertension 2012; 59:614-620. This study highlights an important role of low-dose Ang II, on a background of high salt intake, in chronically elevating RSNA and arterial pressure.
19. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: Role of leptin and sympathetic nervous system. Am J Hypertens 2001; 14:103S-115S.
20. Vaz M, Jennings G, Turner A, et al. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997; 96:3423-3429.
21. Alvarez GE, Beske SD, Ballard TP, et al. Sympathetic neural activation in visceral obesity. Circulation 2002; 106:2533-2536.
22. Grassi G, Dell'Oro R, Facchini A, et al. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22:2363-2369.
23. Lambert GW, Straznicky NE, Lambert EA, et al. Sympathetic nervous activation in obesity and the metabolic syndrome: Causes, consequences and therapeutic implications. Pharmacol Ther 2010; 126:159-172.
24. Iwashita S, Tanida M, Terui N, et al. Direct measurement of renal sympathetic nervous activity in high-fat diet-related hypertensive rats. Life Sciences 2002; 71:537-546.
25. Armitage JA, Burke SL, Prior LJ, et al. Rapid onset of renal sympathetic nerve activation in rabbits fed a high-fat diet. Hypertension 2012; 60:163-171. This article provides important first-time evidence from direct measurements of RSNA in rabbits that obesity-related hypertension may be neurogenic in its origins.
26. Muntzel MS, Al-Naimi OA, Barclay A, et al. Cafeteria diet increases fat mass and chronically elevates lumbar sympathetic nerve activity in rats. Hypertension 2012; 60:1498-1502.
27. Harlan SM,Morgan DA, Agassandian K, et al. Ablation of the leptin receptor in the hypothalamic arcuate nucleus abrogates leptin-induced sympathetic activation. Circ Res 2011; 108:808-812.
28. Prior LJ, Eikelis N, Armitage JA, et al. Exposure to a high-fat diet alters leptin sensitivity and elevates renal sympathetic nerve activity and arterial pressure in rabbits. Hypertension 2010; 55:862-868.
29. Hilzendeger AM, Morgan DA, Brooks L, et al. A brain leptin-renin angiotensin system interaction in the regulation of sympathetic nerve activity. Am J Physiol Heart Circ Physiol 2012; 303:H197-206. This article provides important evidence for a facilitatory role of the renin-angiontensin system in augmenting the central actions of leptin on RSNA responses.
30. Eikelis N, Schlaich M, Aggarwal A, et al. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41:1072-1079.
31. Xiong XQ, Chen WW, Han Y, et al. Enhanced adipose afferent reflex contributes to sympathetic activation in diet-induced obesity hypertension. Hypertension 2012; 60:1280-1286. This study highlights an important role of leptin in mediating adipose afferent reflex induced increases in RSNA and obesity-related hypertension in rats.
32. How JM, Pumpa TJ, Sartor DM. The circulatory and renal sympathoinhibitory effects of gastric leptin are altered by a high fat diet and obesity. Auton Neurosci 2013; 177:95-100.
33. Yamamoto K, Eubank W, Franzke M, et al. Resetting of the sympathetic baroreflex is associated with the onset of hypertension during chronic intermittent hypoxia. Auton Neurosci 2013; 173:22-27.
34. Fardin NM, Oyama LM, Campos RR. Changes in baroreflex control of renal sympathetic nerve activity in high-fat-fed rats as a predictor of hypertension. Obesity (Silver Spring) 2012; 20:1591-1597.
35. Suzuki S, Takeshita A, Imaizumi T, et al. Central nervous system mechanisms involved in inhibition of renal sympathetic nerve activity induced by arginine vasopressin. Circ Res 1989; 65:1390-1399.
36. Zhang ZH, Wei SG, Francis J, et al. Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: The role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 2003; 284:R916-927.
37. McAllen RM, May CN. Differential drives from rostral ventrolateral medullary neurons to three identified sympathetic outflows. Am J Physiol 1994; 267: R935-944.
38. Matsumura K, Tsuchihashi T, Fujii K, et al. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 2002; 40:694-699.
39. Matsumura K, Tsuchihashi T, Abe I. Central cardiovascular action of neuropeptide Y in conscious rabbits. Hypertension 2000; 36:1040-1044.
40. Ramchandra R, Yao ST, May CN. Organ selective regulation of sympathetic outflow by the brain angiotensin system. Curr Hypertens Rep 2013; 15:401-408.
41. Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 1994; 74:323-364.
42. Pyner S, Coote JH. Rostroventrolateral medulla neurons preferentially project to target-specified sympathetic preganglionic neurons. Neuroscience 1998; 83:617-631.
43. Dampney RA, Fontes M, Hirooka Y, et al. Role of angiotensin II receptors in the regulation of vasomotor neurons in the ventrolateral medulla. Clin Exp Pharmacol Physiol 2002; 29:467-472.
44. Davis MI, Filion KB, Zhang D, et al. Effectiveness of renal denervation therapy for resistant hypertension: A systematic review and meta-analysis. J Am Coll Cardiol 2013; 62:231-241. This systematic review and meta-analysis of published renal denervation studies provides strong support for the use of renal denervation as a well tolerated and efficacious treatment option in patients with resistant hypertension.
45. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-ofprinciple cohort study. Lancet 2009; 373:1275-1281.
46. Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932-934.
47. Hering D, Lambert EA, Marusic P, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013; 61:457-464.
48. Roumelioti ME, Buysse DJ, Sanders MH, et al. Sleep-disordered breathing and excessive daytime sleepiness in chronic kidney disease and hemodialysis. Clin J Am Soc Nephrol 2011; 6:986-994.
49. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58:559-565.
50. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: A pilot study. Circulation 2011; 123:1940-1946.
51. Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: A potential new treatment modality for polycystic ovary syndrome J Hypertens 2011; 29:991-996.
52. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol 2011; 58:765-773.
53. Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: Results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012; 6:152-158.
54. Lohmeier TE, Iliescu R, Liu B, et al. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 2012; 59:331-338.